FDA approves Jaypirca for previously untreated CLL/SLL

Overview

Updated Oct 20

The FDA on October 2 cleared Eli Lilly's Jaypirca for newly diagnosed chronic lymphocytic leukemia, the first non-covalent BTK inhibitor approved as initial therapy. The label covers adults without a known 17p deletion, roughly 92% to 95% of new cases.

In Europe, the EMA's Committee for Medicinal Products for Human Use recommended in June that pirtobrutinib be used for CLL across all lines of therapy, and Lilly says EU authorization now covers every line. Lilly is also testing a time-limited regimen: in BRUIN CLL-322, pirtobrutinib plus venetoclax and rituximab improved progression-free survival over venetoclax in previously treated patients.

Why it matters

First-line CLL treatment choices shape years of care; Jaypirca gives newly diagnosed patients a non-covalent option with a milder cardiac profile.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

0.20

Hazard ratio for progression or death vs chemoimmunotherapy

Median PFS not reached for pirtobrutinib vs 33.5 months for bendamustine plus rituximab at 28-month follow-up (p<0.0001)

94%

Overall response rate in pirtobrutinib arm

vs 81% for bendamustine plus rituximab in the BRUIN CLL-313 trial

28%

Serious adverse reaction rate

Serious reactions occurred in 28% of pirtobrutinib patients, most commonly pneumonia (5%)

4th

BTK inhibitors approved for first-line CLL

Jaypirca joins ibrutinib, acalabrutinib, and zanubrutinib in the first-line setting

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Jennifer A. Woyach

Professor and hematologist-oncologist, director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center

Active in CLL research and BTK inhibitor trials

Jacob Van Naarden

Executive vice president and president of Lilly Oncology

Leads Jaypirca commercial strategy at Eli Lilly

Organizations Involved

Eli Lilly and Company

Pharmaceutical company

Manufacturer and marketer of Jaypirca (pirtobrutinib)

Indianapolis-based drugmaker that markets Jaypirca, the first approved non-covalent BTK inhibitor, across mantle cell lymphoma and CLL/SLL.

U.S. Food and Drug Administration

Federal regulator

Approved Jaypirca's first-line CLL/SLL indication on October 2, 2026

The U.S. agency that regulates drugs, biologics, and medical devices; it approved Jaypirca based on the randomized BRUIN CLL-313 trial.

Timeline

May 2019 October 2026

7 events Latest: October 2nd, 2026 · 1 month ago

Tap a bar to jump to that date

October 2026
FDA approves Jaypirca for previously untreated CLL/SLL
Latest Regulatory

Jaypirca becomes the first non-covalent BTK inhibitor available as first-line therapy for CLL/SLL patients without 17p deletion.
October 2nd, 2026
June 2026
EU committee recommends Jaypirca for CLL across all lines
Regulatory

The EMA's Committee for Medicinal Products for Human Use backed pirtobrutinib for adults with CLL regardless of prior BTK inhibitor treatment, based on the BRUIN CLL-313 and BRUIN CLL-314 trials. The application went to the European Commission for a final decision.
June 26th, 2026
December 2025
BRUIN CLL-313 results presented at ASH, published in JCO
Clinical Data

Primary analysis shows pirtobrutinib cuts progression risk by 80% vs bendamustine plus rituximab in previously untreated CLL/SLL without 17p deletion.
December 7th, 2025
FDA converts Jaypirca's CLL/SLL approval to traditional and widens to post-covalent patients
Regulatory

The December 2023 accelerated approval for later-line CLL/SLL becomes a traditional approval, and the label is expanded to adults previously treated with a covalent BTK inhibitor.
December 2025
December 2023
FDA approves Jaypirca for third-line CLL/SLL
Regulatory

Jaypirca wins accelerated approval for adults with CLL/SLL who have had at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
December 2023
January 2023
FDA grants accelerated approval for relapsed mantle cell lymphoma
Regulatory

Jaypirca is approved for relapsed or refractory MCL after two prior lines of therapy, including a BTK inhibitor, on an accelerated basis.
January 27th, 2023
May 2019
Lilly acquires Loxo Oncology, gaining pirtobrutinib
Corporate

Eli Lilly completes its roughly $8 billion acquisition of Loxo Oncology, obtaining the non-covalent BTK inhibitor then known as LOXO-305.
May 31st, 2019

Scenarios

NCCN makes Jaypirca a preferred first-line option

Likely Resolves by End of 2027

Discussed by: Lilly executives and clinical investigators involved in BRUIN CLL-313; NCCN already lists Jaypirca as Category 2A for this population

The NCCN currently recommends Jaypirca as a Category 2A option for previously untreated CLL/SLL without del(17p), specifically for older patients with cardiac comorbidities. If uptake grows and guideline authors weigh the efficacy and safety data more heavily, they could upgrade it to Category 1 (preferred), placing it on equal footing with ibrutinib, acalabrutinib, and zanubrutinib. That would signal that doctors are using it early, not holding it in reserve.

FDA expands first-line label to include 17p deletion patients

Unlikely Resolves by End of 2028

Discussed by: MedPath trial database analysis noting roughly 5-8% of newly diagnosed CLL/SLL patients carry 17p deletion

The current label excludes patients with known 17p deletion, a high-risk genomic subgroup with worse outcomes. Expanding the indication would require new data from a trial that includes these patients, likely testing pirtobrutinib alone or with venetoclax in high-risk CLL. A positive readout would broaden Jaypirca's first-line reach to nearly all newly diagnosed patients.

Rival non-covalent BTK inhibitor reaches market, ending class monopoly

Possible Resolves by Q2 2028

Discussed by: Merck's nemtabrutinib program, another non-covalent BTK inhibitor in clinical development

Jaypirca is currently the only approved non-covalent BTK inhibitor, which supports its pricing power and its 'save it for later' rationale. If Merck's nemtabrutinib or another reversible BTK inhibitor wins FDA approval for CLL/SLL, doctors would gain a second option in the class, and Jaypirca's uniqueness would erode. Lilly's first-line positioning would then face direct competition within its own mechanism.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

March 2016

Ibrutinib first-line CLL approval (2016)

Ibrutinib, the first covalent BTK inhibitor, won FDA approval for previously untreated CLL in March 2016 after the RESONATE-2 trial showed it beat chlorambucil in patients 65 and older. It marked the beginning of the end for chemoimmunotherapy as the CLL standard of care.

Then

Oral targeted therapy became the new first-line standard for many CLL patients within a few years.

Now

Ibrutinib and successor drugs turned CLL from a disease managed with chemotherapy into a chronically managed condition, opening the way for multiple BTK inhibitors to compete in the first-line setting.

Why this matters now

Jaypirca extends the same shift a decade later, but now the newcomer must compete with three established covalent inhibitors and justify early use rather than being held in reserve for resistant disease.

2006-2007

Second-generation TKIs in chronic myeloid leukemia (2006-2007)

Imatinib turned CML from a fatal leukemia into a chronic disease in the early 2000s. When patients relapsed on imatinib due to kinase mutations, dasatinib (approved 2006) and nilotinib (2007) were developed specifically to overcome those mutations.

Then

The new drugs rescued many imatinib-resistant patients and became additional options within the same drug class.

Now

Established the model of sequencing next-generation kinase inhibitors within a class and of designing successors to beat resistance mutations.

Why this matters now

Jaypirca plays the analogous next-generation role for BTK inhibitors, covering the C481S mutation that defeats covalent drugs — exactly why some doctors want to reserve it for later lines of therapy.

Sources

(9)